Vabysmo

Adult patients w/ neovascular (wet) age-related macular degeneration (nAMD); visual impairment due to diabetic macular edema (DME); macular edema secondary to retinal vein occlusion (RVO).

Intravitreal inj nAMD 6 mg (0.05 mL) every 4 wk for the 1st 4 doses. May modify dosing interval by assessment of disease activity based on anatomic & visual acuity evaluations 20 &/or 24 wk after treatment initiation. DME 6 mg (0.05 mL) every 4 wk for at least 4 doses or until macular edema is resolved based on central subfield thickness of macula as measured by optical coherence tomography. May extend up to every 16 wk in up to 4-wk increments. RVO 6 mg (0.05 mL) every 4 wk; ≥3 consecutive mthly inj may be needed. May be extended in up to 4-wk increments.

Hypersensitivity. Patients w/ ocular or periocular infections; active intraocular inflammation.

Other Eye Preparations

S01LA09 - faricimab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

POM